Sarepta acquires Myonexus, reports LGMD trial results
Sarepta Therapeutics Inc. (NASDAQ:SRPT) exercised its option to acquire Myonexus Therapeutics Inc. (New Albany, Ohio), giving it a pipeline of five gene therapy candidates to treat forms of limb-girdle muscular dystrophy (LGMD). Sarepta also revealed efficacy data from a Phase I/II trial of one of the candidates, MYO-101, in a cohort of patients with LGMD type 2E; the results exceeded expectations.
Sarepta paid $165 million to exercise the buyout option, which it acquired in May 2018 for $60 million up front. Along with the type 2E candidate, Sarepta gains gene therapies to treat LGMD types 2D, 2B, 2C and 2L. Besides MYO-101, two programs have reached the clinic: MYO-102 for LGMD type 2D has been tested in a Phase I/II trial, while MYO-201 for type 2B has reached Phase I testing...